Atopic Dermatitis
Latest News
FDA extends Dupixent indication for 12- to 17-year-olds
While there are several systemic medications used as second-line therapy for treatment of pediatric AD, dupilumab is the first FDA-approved...
Conference Coverage
Atopic dermatitis at 1 year links with persistent food allergies
SAN FRANCISCO – Infants with atopic dermatitis at 1 year old that persists showed an elevated prevalence of food...
From the Journals
Don’t discount sleep disturbance for children with atopic dermatitis
Longitudinal data from more than 13,000 children show that those with atopic dermatitis suffer significantly impaired sleep quality.
Conference Coverage
Age 1 food allergies often disappear by age 6
SAN FRANCISCO – Peanut or egg allergies diagnosed in 1-year-olds often were gone by the time the child turned 6.
Conference Coverage
Pediatric pruritus requires distinct approach to assessment and management
WASHINGTON – Issues related to quality of life differ between children and adults, and assessing itch severity in...
Conference Coverage
Eczema increases the risk of impaired mental health among children
WASHINGTON – Many children with eczema and impaired mental health may not be receiving appropriate psychological...
From the Journals
Atopic dermatitis associated with increased suicidality
The disease is associated with high levels of proinflammatory cytokines, which have been isolated in the cerebrospinal fluid of patients who have...
Conference Coverage
New worldwide atopic dermatitis survey brings big surprises
PARIS – Findings of the huge 18-nation survey triggers reconsideration of adult atopic dermatitis.
From the Journals
Gestational, umbilical cord vitamin D levels don’t predict atopic disease in offspring
Vitamin D levels measured in maternal sera during gestation and in umbilical cord blood were not predictive of the prevalence of eczema, food...
From the Journals
Review of pediatric data indicates link between vitamin D levels and atopic dermatitis severity
Data on vitamin D supplementation and AD severity “suggested potential benefit but were conflicting.”
News
FDA accepts priority review of dupilumab for adolescent atopic dermatitis
Phase 3 study results of dupilumab in patients aged 12-17 years with atopic dermatitis were submitted to the agency.